Iovance Biotherapeutics stock: At Lang & Schwarz, Iovance Biotherapeutics stock falls 7.15 percent
Published on 10/22/2026 at 19:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPrice and analyst signals
- Iovance Biotherapeutics stock fell 7.15 percent at Lang & Schwarz on October 22, 2026.
- Second-quarter 2026 revenue reached USD 99.31 million, 13.07 percent above consensus.
- Iovance Biotherapeutics stock costs EUR 12.33 at Lang & Schwarz, 7.15 percent below the Frankfurt close of October 21, 2026.
Iovance Biotherapeutics stock fell 7.15 percent against the Frankfurt close of October 21, 2026, with the euro quotation at Lang & Schwarz reaching EUR 12.33 on October 22, 2026 at 7:01 p.m. CEST. The move puts the price report ahead of the latest analyst and operating figures for investors assessing the commercial ramp of Amtagvi.
Revenue beat expectations
Iovance Biotherapeutics reported second-quarter 2026 revenue of USD 99.31 million, compared with consensus of USD 87.83 million, a 13.07 percent gap. MarketBeat also reported an adjusted loss of USD 0.11 per share against an expected adjusted loss of USD 0.13 per share. The revenue figure was up 65.70 percent from the second quarter of 2025.
Price position after the decline
The primary listing is on Nasdaq, where IOVA was last quoted at USD 13.77 on October 22, 2026 at 1:04 p.m. ET while the market was open. The Nasdaq quote sat inside a 52-week range of USD 1.76 to USD 15.37, and the session volume had reached 5,043,487 shares.
That USD quotation was 10.41 percent below the 52-week high and 682.39 percent above the 52-week low. The euro price cannot be compared directly with the USD range, so the German quotation and the Nasdaq range remain separate market views.
Analyst target and reporting date
Jefferies reiterated a Buy rating and a USD 20.00 price target in a report dated October 12, 2026, according to Business Insider. Against the USD 13.77 Nasdaq quotation, that target stands 45.24 percent above the price. The same report cited a USD 14.40 average target, which would be 4.57 percent above the Nasdaq quotation.
MarketBeat said on October 14, 2026 that 13 firms covered the company, including nine Buy ratings, three Holds and one Sell. Its average target was USD 13.20, 4.14 percent below the Nasdaq quotation, creating a more cautious counterpoint to the Jefferies target.
Trading view for investors
The current picture combines a sharp German-market decline with a Nasdaq quotation below the recent high. Operating evidence remains more constructive: second-quarter revenue exceeded estimates and the adjusted loss was narrower than expected, while the spread between published targets shows how differently analysts value the launch trajectory.
The further course of trading is shown by the continuously updated real-time quote of Iovance Biotherapeutics stock.
Iovance Biotherapeutics market data
- Company: Iovance Biotherapeutics, Inc.
- ISIN: US4622601007
- Ticker: IOVA
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 22, 2026, 7:01 p.m. CEST): EUR 12.33
- Change versus Frankfurt close: minus 7.15 percent
- Frankfurt close (October 21, 2026): EUR 13.28
- Market capitalization: USD 6.2 billion (as of October 22, 2026)
- 52-week range: USD 1.76-15.37 (as of October 22, 2026)
- Sector / Industry: Health care / Biotechnology
Market context: Market report Nasdaq Composite.
